We speak to medical oncologist Narjust Duma, from the University of Wisconsin in the USA, about COVID-19 vaccination in people with cancer, discussing issues such as vaccine timing, side-effects, and key unanswered research questions.

In this Medicine Matters oncology podcast, we speak to Gary Lyman (Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, USA) about the impact of the COVID-19 outbreak on the conduct of cancer clinical trials. Find more on Medicine Matters oncology: https://bit.ly/Lyman-COVID-19-podcast

Co-project leader Lennard Lee talks about the inception and development of the initiative that will provide insight into the impact of COVID-19 on people with cancer and facilitate shared learning that will benefit patient care. Find more on Medicine Matters oncology: https://bit.ly/Lee-COVID-19-podcast

Gilberto Lopes (Sylvester Comprehensive Cancer Center at the University of Miami, Florida, USA), a steering committee member of CCC19, tells us about the registry collating data on cancer patients with comorbid COVID-19 to provide an evidence base for future decision-making. Find more on Medicine Matters oncology: https://bit.ly/Lopes-COVID-19-podcast Image credit: © koto_feja/Getty Images/iStock

Thoracic oncology nurse practitioner Beth Sandy explains how the coronavirus pandemic is affecting cancer patient care and how strategies such as telemedicine are coming into their own. Find more on Medicine Matters oncology: http://bit.ly/Sandy-COVID-19-podcast Image credit: Coronavirus illustration © dottedyeti/stock.adobe.com

Genitourinary oncologists Cora Sternberg (Weill Cornell Medicine, New York, USA) and Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) share their experience of managing cancer patients during the COVID-19 pandemic, comparing perspectives from a US and German stand point. Find more on Medicine Matters oncology: http://bit.ly/Sternberg-COVID-19-podcast

Gilberto Lopes discusses the impact of the COVID-19 pandemic on the management of patients with lung cancer and outlines the measures being implemented to minimize the risk for patients. Find more on Medicine Matters oncology: http://bit.ly/MM-oncology-podcasts

Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the KRAS G12C mutation –  in patients with locally advanced or metastatic non-small-cell lung cancer. Find more on Medicine Matters oncology: http://bit.ly/Lindsay-podcast-WCLC-2019 More from WCLC 2019: http://bit.ly/WCLC-2019-coverage

Recent research has shown an association between intestinal microbiota and response to immunotherapy in the setting of various tumor types. Listen to Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, share her insights into the findings. Find more on Medicine Matters oncology http://bit.ly/Wargo-Gut-microbiome-immunotherapy This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on January 28, 2019.

Hashim Ahmed takes us through the COMPARE study which showed that men with localized prostate cancer are willing to accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research. Find more on Medicine Matters oncology http://bit.ly/Ahmed-COMPARE-study-podcast This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on November 15, 2018.

Professor Mel Greaves (Institute of Cancer Research, London, UK) discusses his proposed theory for the etiology of childhood acute lymphoblastic leukemia, in which early microbial exposure plays a key role. He outlines the evidence supporting the hypothesis and delves into the implications. Find more on Medicine Matters oncology http://bit.ly/Greaves-ALL-and-infection This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on October 15, 2018.

Advisory Board member and study author Paul Nathan, from the Mount Vernon Cancer Centre in Middlesex, UK, discusses the phase III SUMIT trial, which evaluated the addition of the MEK inhibitor selumetinib to dacarbazine in patients with metastatic uveal melanoma. Find more on Medicine Matters oncology http://bit.ly/Nathan-SUMIT-trial This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on May 4, 2018.

Fabien Maldonado, from Vanderbilt UMC in Nashville, Tennessee, USA, provides an independent comment on the AMPLE trial, published in JAMA, which aimed to establish the more effective technique for reducing the number of hospitalization days in patients with malignant pleural effusion. Find more on Medicine Matters oncology http://bit.ly/Maldonado-AMPLE-trial This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on January 2, 2018.

The phase III GOG 240 trial evaluated bevacizumab in women with advanced cervical cancer - Advisory Board member and lead investigator Krishnansu Tewari outlines the results of the final analysis in this podcast. Find more on Medicine Matters oncology: http://bit.ly/Tewari-GOG-240-trial This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on December 12, 2017.